Barasertib (AZD1152-HQPA)

Catalog No.S1147

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Price Stock Quantity  
USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Barasertib (AZD1152-HQPA) Chemical Structure

Barasertib (AZD1152-HQPA) Chemical Structure
Molecular Weight: 507.56

Validation & Quality Control

8 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Barasertib (AZD1152-HQPA) is available in the following compound libraries:

Aurora Kinase Inhibitors with Unique Features

  • Pan Aurora Kinase Inhibitors

    Danusertib (PHA-739358) Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM. SNS-314 Mesylate Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.

  • Most Potent Aurora Kinase Inhibitor

    MK-5108 (VX-689) Aurora A, IC50=0.064 nM.

  • Aurora Kinase Inhibitor in Clinical Trial

    Alisertib (MLN8237) Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.

  • Classic Aurora Kinase Inhibitor

    Hesperadin Potently inhibits Aurora B with IC50 of 250 nM.

Product Information

  • Compare Aurora Kinase Inhibitors
    Compare Aurora Kinase Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Targets Aurora B [1]
(Cell-free assay)
Aurora A [1]
(Cell-free assay)
IC50 0.37 nM 1368 nM
In vitro AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LNCaPNEOyVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXiZVZ[OC13MECgcm0>NWnTTmdmPDkEoHi=NITSSZVKSzVyPUK1JI5ONXTtNVNjOjV{N{e2OVk>
LNCaPMVXBdI9xfG:|aYOgRZN{[Xl?NVrxTZFsOC13MECgcm0>MVO0POKhcA>?Mnq0bY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bEB1cHKxdXfoJINie3Cjc3WtN{B2eHKnZ4XsZZRqd25?NF3MNpMzPTJ5N{[1PS=>
LNCaPNIOwVoJHfW6ldHnvckBCe3OjeR?=MYO1NEBvVQ>?NYrQVGc3PDhiaB?=MkHPbY5lfWOnczDtbYNzd263Y3zlbUB4cXSqIHHu[ZVo\W6rYzDt[YNp[W6rc32=NUTUe3pbOjV{N{e2OVk>
RamosMX\GeY5kfGmxbjDBd5NigQ>?M2DnWFUxOCCwTR?=NFPFWWoxNTd{IHi=M1PZUYlvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?=MlrQNlE{PzF2NE[=
Daudi MVrGeY5kfGmxbjDBd5NigQ>?NEnNZnk2ODBibl2=NUjxfGpLOC15MjDoMoHSbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOnMUSyNVM4OTR2Nh?=
L540M2nCWWZ2dmO2aX;uJGF{e2G7MVi1NFAhdk1?NYLCZZNQOC15MjDoMnnybY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOnNHvCSmgzOTN5MUS0Oi=>
BJAJNH3FV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PhWVUxOCCwTR?=NHr2bZYxNTd{IHi=MlL1bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?=MVmyNVM4OTR2Nh?=
RamosMl:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrtOVAxKG6PMly4NE04OiCqM{jpNYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=NGnZV48zOTN5MUS0Oi=>
RajiM1iwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX:1NFAhdk1?MnLzNE04OiCqM1ixNYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=NYP1dGRmOjF|N{G0OFY>
Daudi NXHiR2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPm[|E2ODBibl2=M2TiVFAuPzJiaB?=MXrpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7MVGyNVM4OTR2Nh?=
L428NH7Ke|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jUSFUxOCCwTR?=NFzLPIIxNTd{IHi=NIrDfIJqdmirYnn0d{Bk\WyuIHfyc5d1cA>?MW[yNVM4OTR2Nh?=
KM-H2NH\NeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrSc2V[PTByIH7NMV:wMVczKGh?M2TINIlvcGmkaYTzJINmdGxiZ4Lve5RpM37BZVIyOzdzNES2
HDLM-2NGTKWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M12yXFUxOCCwTR?=NYLyZmJKOC15MjDoNFP0U4tqdmirYnn0d{Bk\WyuIHfyc5d1cA>?MYGyNVM4OTR2Nh?=
L450M4fOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInZcVI2ODBibl2=M3nNUlAuPzJiaB?=NXj1XG5TcW6qaXLpeJMh[2WubDDndo94fGh?MlT4NlE{PzF2NE[=
BJAJMnvZRZBweHSxc3nzJGF{e2G7MnzJOVAxKG6PMVqwMVczKGh?NU\WO5pIcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>NXK0XmJ3OjF|N{G0OFY>
RamosMWrBdI9xfG:|aYOgRZN{[Xl?NYj1UFg3PTByIH7NM2\U[FAuPzJiaB?=MonWbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK=M3e0cVIyOzdzNES2
RajiMWTBdI9xfG:|aYOgRZN{[Xl?M3nyWlUxOCCwTR?=NXXOXGR6OC15MjDoMVPpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=NFX5ZpIzOTN5MUS0Oi=>
Daudi M{\mZmFxd3C2b4Ppd{BCe3OjeR?=NYfmZZBYPTByIH7NNGfRc4kxNTd{IHi=MnLkbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK=NHfGeGkzOTN5MUS0Oi=>
L428NGLOS4FCeG:ydH;zbZMhSXO|YYm=MmXMOVAxKG6PMUmwMVczKGh?NXrrOY9qcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>NInySYQzOTN5MUS0Oi=>
KM-H2NEmxc|JCeG:ydH;zbZMhSXO|YYm=MWi1NFAhdk1?NUXnZ5FZOC15MjDoM3PYZ4lv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyM37MblIyOzdzNES2
HDLM-2MXjBdI9xfG:|aYOgRZN{[Xl?NXvReWN{PTByIH7NNUTTVpZ1OC15MjDoNYXMSppQcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>NFX6NXUzOTN5MUS0Oi=>
L450NIXu[VZCeG:ydH;zbZMhSXO|YYm=M1rsZVUxOCCwTR?=NEDtTowxNTd{IHi=NH;nfHJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>NH24XJUzOTN5MUS0Oi=>
SW620Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVmyV49[TUN3ME2xNOKyOi5zIH7NMUSyNVI1PTB7MB?=
HCT116NVjZfVg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\ISWM2OD1zMdMxN{4{KG6PMkX0NlEzPDVyOUC=
MDA-MB-435MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fnW|AuOTByMECgcm0>NH3OelYzNTViZB?=M3rYSWROW09?NVjjc|FPUUN3ME2xNlUhdk1?NGi1TFYzODF5NUmyOi=>
MDA-MB-468Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\GRZMxNTFyMECwJI5OM{nHXFIuPSCmM1PlT2ROW09?M1WzZWlEPTB;MUSgcm0>NGjMWowzODF5NUmyOi=>
MDA-MB-231NGrLVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPNV44xNTFyMECwJI5OMoXuNk02KGR?Mn;aSG1UVw>?NVvTXYJWUUN3ME2xNFUhdk1?Mn;uNlAyPzV7Mk[=
BT474M3z3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVOwMVExODByIH7NMoDXNk02KGR?M4Xqb2ROW09?NV\sT|NCUUN3ME24JI5OM{XnclIxOTd3OUK2
MDA-MB-361Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1K3OFAuOTByMECgcm0>NWjNepp[Oi13IHS=MknTSG1UVw>?NIDGR3BKSzVyPUewJI5OM1fXc|IxOTd3OUK2
HER18MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWiwMVExODByIH7NMlTKNk02KGR?M2H6WGROW09?MYfJR|UxRTJyIH7NMoflNlAyPzV7Mk[=
HER18Mm[4RZBweHSxc3nzJGF{e2G7MkHzNVAxKG6PM2jtb|AwOjRxNEigbC=>NUfwZ2V3TE2VTx?=NYHVN4lycW6mdXPld{BieG:ydH;zbZMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDwc5RmdnSrYXy=MkPuNlAyPzV7Mk[=
MDA-MB-231NGTBU5BCeG:ydH;zbZMhSXO|YYm=MnzzNVA2KG6PM4Dv[FAwOjRxNEigbC=>NULGdmQzTE2VTx?=MorzbY5lfWOnczDhdI9xfG:|aYOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yCyb4TlcpRq[Wx?NFvzZ4ozODF5NUmyOi=>
JHH-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHW3[2IxNjQkgKOxNFAxyqCwTR?=M1jCb|czKGh?M4jObWVEPTB;MUeuOOKyOS5yIH7NMVSxPVkyOzl|NR?=
JHH-2NHHRe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELrTJcxNjQkgKOxNFAxyqCwTR?=NXXtUlBpPzJiaB?=M4\3SGVEPTB;MkG4MlDDuTFyLkigcm0>NXP4R5VEOTl7MUO5N|U>
JHH-4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV:4VpQ2OC5|4pETNVAxOMLibl2=NXe4W4xFPzJiaB?=NUTFeHFUTUN3ME2xOVUvPsLzMU[uPEBvVQ>?NGP5NI0yQTlzM{mzOS=>
HuH-1M2DyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPLNE4{6oDVMUCwNOKhdk1?NIDOS2w4OiCqNILiU41GSzVyPUK3MlPDuTVwMDDuUS=>NHn2ZWIyQTlzM{mzOS=>
HuH-6MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInOXmQxNjQkgKOxNFAxyqCwTR?=MYS3NkBpMlLHSWM2OD1|LkhCtVAvPiCwTR?=Mn7hNVk6OTN7M{W=
HuH-7M4Kxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVGwMlPjiJNzMECwxsBvVQ>?NVT5dnpHPzJiaB?=MWfFR|UxRTZwONMxNE4{KG6PNUDYVHVmOTl7MUO5N|U>
HLEM{LRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFrDOG4xNjQkgKOxNFAxyqCwTR?=NV\5e|VPPzJiaB?=Mn3SSWM2OD12NT65xtE3NjRibl2=NVzrU4VVOTl7MUO5N|U>
HLFNV;U[3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3ZSZZ{OC5|4pETNVAxOMLibl2=MX23NkBpM3ewcWVEPTB;MUK2MlHDuTF{LkKgcm0>NG\NVYcyQTlzM{mzOS=>
PLC/PRF/5NHqyO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYiwMlPjiJNzMECwxsBvVQ>?M1fYclczKGh?Ml7ISWM2OD15Nj65xtE6Njlibl2=MmToNVk6OTN7M{W=
SK-Hep1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXNNE4{6oDVMUCwNOKhdk1?M2jEcFczKGh?MY\FR|UxRTJzLkpCtVEvOiCwTR?=NUPldGFxOTl7MUO5N|U>
Hep3BNVznTW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTqNE4{6oDVMUCwNOKhdk1?NVLDUGJ1PzJiaB?=NF3hVmxGSzVyPUeuOuKyOS5{IH7NM1\Y[lE6QTF|OUO1
HepG2NXHu[|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjmUYZbOC5|4pETNVAxOMLibl2=NFXmS3A4OiCqNYPsT4JJTUN3ME2xOE44yrFzLkegcm0>MWKxPVkyOzl|NR?=
RamosM13iTmFxd3C2b4Ppd{BCe3OjeR?=M{ewVFI2NzVyL{GwNEBvVQ>?MX:0PEBpNGT2UZNqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM>NXL5c3NMOTl6MkOxOlg>
Daudi M{D0bmFxd3C2b4Ppd{BCe3OjeR?=Mo\tNlUwPTBxMUCwJI5OMnXIOFghcA>?NXfhOYtPcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{M4njc|E6QDJ|MU[4
BALM-14M4nkTWFxd3C2b4Ppd{BCe3OjeR?=NWnMV41MOTJwNT:yOU82OCCwTR?=Mnm1OFghcA>?MlH6bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCzMUWxPVgzOzF4OB?=
BALM-27NGj5eIlCeG:ydH;zbZMhSXO|YYm=MnvpNVIvPS9{NT:1NEBvVQ>?MnH3OFghcA>?M{HXbIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=>MYqxPVgzOzF4OB?=
NB4NYfTfGViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV6wMlAyNzBwMT:xJO69VQ>?M4nGdFQ5KGh?MUjpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7NGP3blYyQDN4N{S4OC=>

... Click to View More Cell Line Experimental Data

In vivo Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
Concentrations Dissolved in DMSO, final concentrations ~100 nM
Incubation Time 24 or 48 hours
Method Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.

Animal Study: [1]

Animal Models Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
Formulation Dissolved in 3M Tris, pH 9.0, at a concentration of 2.5 mg/mL
Dosages 5 or 25 mg/kg
Administration Intraperitoneal injection 4 times a week or every another day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yang J, et al. Blood, 2007, 110(6), 2034-2040.

[2] Wilkinson RW, et al. Clin Cancer Res, 2007, 13(12), 3682-3688.

Chemical Information

Download Barasertib (AZD1152-HQPA) SDF
Molecular Weight (MW) 507.56
Formula

C26H30FN7O3

CAS No. 722544-51-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms INH 34
Solubility (25°C) * In vitro DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(5-(7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-ylamino)-1H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Aurora Kinase Products

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • ML141

    ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.

  • Alisertib (MLN8237)

    Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

    Features:First orally available inhibitor of Aurora A.

  • VX-680 (Tozasertib, MK-0457)

    VX-680 (Tozasertib, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.

  • ZM 447439

    ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

    Features:An Aurora selective ATP-competitive inhibitor.

  • MLN8054

    MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.

  • MK-5108 (VX-689)

    MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.

  • Aurora A Inhibitor I

    Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

    Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Recently Viewed Items

Tags: buy Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) supplier | purchase Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) cost | Barasertib (AZD1152-HQPA) manufacturer | order Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us